StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.80+0.10 (+0.60%)

Close on Nov 17, 2026Market cap $3.06BP/E –Yield –

Xeris Biopharma total assets

Total assets on the balance sheet at the end of each period.

Xeris Biopharma's total assets was $411.91M at Jun 30, 2026. For fiscal 2025 it was $383.53M, up 18.7% from the year before. The highest annual figure on record is $383.53M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$383.53M+18.7%
FY2024Dec 31, 2024$323.06M+0.1%
FY2023Dec 31, 2023$322.60M-6.4%
FY2022Dec 31, 2022$344.52M+13.2%
FY2021Dec 31, 2021$304.36M+91.2%
FY2020Dec 31, 2020$159.15M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$411.91M+23.1%
Q1 FY2026Mar 31, 2026$392.01M+24.3%
Q4 FY2025Dec 31, 2025$383.53M+18.7%
Q3 FY2025Sep 30, 2025$370.19M+15.3%
Q2 FY2025Jun 30, 2025$334.69M+0.9%
Q1 FY2025Mar 31, 2025$315.45M-6.3%
Q4 FY2024Dec 31, 2024$323.06M+0.1%
Q3 FY2024Sep 30, 2024$321.10M-2.0%
Q2 FY2024Jun 30, 2024$331.73M+0.9%
Q1 FY2024Mar 31, 2024$336.62M+4.7%
Q4 FY2023Dec 31, 2023$322.60M-6.4%
Q3 FY2023Sep 30, 2023$327.78M+8.2%
Q2 FY2023Jun 30, 2023$328.78M+3.2%
Q1 FY2023Mar 31, 2023$321.36M-4.8%
Q4 FY2022Dec 31, 2022$344.52M+13.2%
Q3 FY2022Sep 30, 2022$303.02M+130.9%
Q2 FY2022Jun 30, 2022$318.62M+100.2%
Q1 FY2022Mar 31, 2022$337.62M–
Q4 FY2021Dec 31, 2021$304.36M–
Q3 FY2021Sep 30, 2021$131.26M–
Q4 FY2020Dec 31, 2020$159.15M–

More Xeris Biopharma figures

See a number that looks wrong?